Biosimilar development

Intense medical development and the introduction of therapeutic proteins challenges pharmaceutical companies with a new family of active substances - biosimilars - and drugs known as biobetters.

With the appropriate skills in this area we can offer the service necessary to prepare the final form of biosimilars, ready for clinical trials.

These services include:
• the provision of protein preparations;
• the determination of the pharmacokinetics of the active substance 
• the determination of the cytotoxicity of the active substance.

By 2012, our research division that works on proteins plans to expand its business profile and have the facility to become a partner also in projects during phase 1 and 2 of clinical trials.